SI3000810T1 - N3-alkiliran derivat benzimidazola kot zaviralec mek - Google Patents

N3-alkiliran derivat benzimidazola kot zaviralec mek

Info

Publication number
SI3000810T1
SI3000810T1 SI200332546T SI200332546T SI3000810T1 SI 3000810 T1 SI3000810 T1 SI 3000810T1 SI 200332546 T SI200332546 T SI 200332546T SI 200332546 T SI200332546 T SI 200332546T SI 3000810 T1 SI3000810 T1 SI 3000810T1
Authority
SI
Slovenia
Prior art keywords
mek inhibitor
benzimidazole derivative
alkylated benzimidazole
alkylated
derivative
Prior art date
Application number
SI200332546T
Other languages
English (en)
Slovenian (sl)
Inventor
Eli M. Wallace
Joseph P. Lyssikatos
Brian T. Hurley
Allison L. Marlow
Original Assignee
Array Biopharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28041856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3000810(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc. filed Critical Array Biopharma Inc.
Publication of SI3000810T1 publication Critical patent/SI3000810T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
SI200332546T 2002-03-13 2003-03-13 N3-alkiliran derivat benzimidazola kot zaviralec mek SI3000810T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36400702P 2002-03-13 2002-03-13
EP15177189.6A EP3000810B1 (en) 2002-03-13 2003-03-13 N3 alkylated benzimidazole derivative as mek inhibitor

Publications (1)

Publication Number Publication Date
SI3000810T1 true SI3000810T1 (sl) 2017-10-30

Family

ID=28041856

Family Applications (4)

Application Number Title Priority Date Filing Date
SI200332546T SI3000810T1 (sl) 2002-03-13 2003-03-13 N3-alkiliran derivat benzimidazola kot zaviralec mek
SI200331731T SI1482932T1 (sl) 2002-03-13 2003-03-13 N3-alkilirani derivati benzimidazola kot inhibitorji mek
SI200332449T SI2275102T1 (sl) 2002-03-13 2003-03-13 N3 alkilirani benzimidazol derivati kot MEK inhibitorji
SI200332221T SI2130537T1 (sl) 2002-03-13 2003-03-13 N3-alkilirani derivati benzimidazola kot inhibitorji mek

Family Applications After (3)

Application Number Title Priority Date Filing Date
SI200331731T SI1482932T1 (sl) 2002-03-13 2003-03-13 N3-alkilirani derivati benzimidazola kot inhibitorji mek
SI200332449T SI2275102T1 (sl) 2002-03-13 2003-03-13 N3 alkilirani benzimidazol derivati kot MEK inhibitorji
SI200332221T SI2130537T1 (sl) 2002-03-13 2003-03-13 N3-alkilirani derivati benzimidazola kot inhibitorji mek

Country Status (35)

Country Link
US (11) US20030232869A1 (cg-RX-API-DMAC7.html)
EP (5) EP1482932B1 (cg-RX-API-DMAC7.html)
JP (4) JP4093966B2 (cg-RX-API-DMAC7.html)
KR (3) KR100984613B1 (cg-RX-API-DMAC7.html)
CN (4) CN101486682B (cg-RX-API-DMAC7.html)
AR (3) AR038971A1 (cg-RX-API-DMAC7.html)
AT (1) ATE449605T1 (cg-RX-API-DMAC7.html)
AU (2) AU2003218157C1 (cg-RX-API-DMAC7.html)
BE (1) BE2019C510I2 (cg-RX-API-DMAC7.html)
BR (1) BR122018007328B8 (cg-RX-API-DMAC7.html)
CA (1) CA2478374C (cg-RX-API-DMAC7.html)
CL (2) CL2012002381A1 (cg-RX-API-DMAC7.html)
CY (3) CY1109727T1 (cg-RX-API-DMAC7.html)
DE (1) DE60330227D1 (cg-RX-API-DMAC7.html)
DK (4) DK2130537T3 (cg-RX-API-DMAC7.html)
DO (4) DOP2003000613A (cg-RX-API-DMAC7.html)
ES (5) ES2407849T3 (cg-RX-API-DMAC7.html)
FR (1) FR19C1014I2 (cg-RX-API-DMAC7.html)
HU (2) HUE025767T2 (cg-RX-API-DMAC7.html)
IL (4) IL163995A0 (cg-RX-API-DMAC7.html)
IS (4) IS2748B (cg-RX-API-DMAC7.html)
LT (1) LTC1482932I2 (cg-RX-API-DMAC7.html)
LU (1) LUC00100I2 (cg-RX-API-DMAC7.html)
MX (1) MXPA04008893A (cg-RX-API-DMAC7.html)
NL (1) NL300974I2 (cg-RX-API-DMAC7.html)
NZ (1) NZ535158A (cg-RX-API-DMAC7.html)
PA (1) PA8569301A1 (cg-RX-API-DMAC7.html)
PL (5) PL230179B1 (cg-RX-API-DMAC7.html)
PT (4) PT2275102E (cg-RX-API-DMAC7.html)
SG (3) SG2013013339A (cg-RX-API-DMAC7.html)
SI (4) SI3000810T1 (cg-RX-API-DMAC7.html)
TW (3) TWI343377B (cg-RX-API-DMAC7.html)
UA (1) UA77765C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003077914A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200407220B (cg-RX-API-DMAC7.html)

Families Citing this family (262)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA77765C2 (en) 2002-03-13 2007-01-15 Array Biopharma Inc N3 alkylated derivatives of benzimidazole as mek inhibitors
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1581527A4 (en) * 2002-12-13 2006-11-22 Smithkline Beecham Corp MIMETICS OF THROMBOPOIETINE
ES2324165T3 (es) * 2003-02-26 2009-07-31 Kowa Co., Ltd. Tratamiento de la dermatitis alergica de contacto.
ATE442847T1 (de) * 2003-07-24 2009-10-15 Warner Lambert Co Benzimidazol-derivate als mek-hemmer
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
BRPI0414581C1 (pt) 2003-09-22 2021-05-25 Mei Pharma Inc composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
HRP20110105T4 (hr) * 2003-11-19 2013-03-31 Array Biopharma, Inc. Mek heterocikliäśki inhibitori
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
PH12012501891A1 (en) * 2003-11-21 2013-09-02 Array Biopharma Inc Akt protein kinase inhibitors
WO2005058341A2 (en) * 2003-12-11 2005-06-30 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
WO2006045514A1 (en) 2004-10-20 2006-05-04 Applied Research Systems Ars Holding N.V. 3-arylamino pyridine derivatives
ES2330872T3 (es) * 2004-12-01 2009-12-16 Merck Serono Sa Derivados de (1,2,4)triazolo(4,3-a)piridina para el tratamiento de enfermedades hiperproliferativas.
US7429667B2 (en) * 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
BRPI0610139A2 (pt) * 2005-05-18 2010-06-01 Array Biopharma Inc inibidores heterocìclicos de mek e métodos de uso dos mesmos
KR101357361B1 (ko) * 2005-06-23 2014-02-03 아스트라제네카 아베 벤즈이미다졸 화합물의 ＳｎＡｒ 제조 방법
EP1904481B1 (en) 2005-06-23 2016-02-17 Array Biopharma, Inc. Process for preparing benzimidazole compounds
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
AU2012261703B2 (en) * 2005-10-07 2015-08-13 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
AU2013203939B2 (en) * 2005-10-07 2015-08-13 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
CA2622755C (en) * 2005-10-07 2017-01-31 Exelixis, Inc. Azetidines as mek inhibitors
US7968108B2 (en) * 2005-10-25 2011-06-28 Metbro Distributing L.P. Hydrogen cyanamide pesticide formulations
US7572460B2 (en) * 2005-10-25 2009-08-11 Rodrigo Rodriguez-Kabana Hydrogen cyanamide pesticide formulations
RU2418790C3 (ru) * 2005-12-21 2022-03-14 Астразенека Аб Новая гидросульфатная соль
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
JP2009520780A (ja) * 2005-12-21 2009-05-28 アストラゼネカ アクチボラグ 癌の治療において有用なｍｅｋ阻害剤である６−（４−ブロモ−２−クロロフェニルアミノ）−７−フルオロ−ｎ−（２−ヒドロキシエトキシ）−３−メチル−３ｈ−ベンゾイミダゾール−５−カルボキシアミドのトシル酸塩
CA2534243A1 (fr) 2006-01-25 2007-07-25 Hydro Quebec Particules d'oxyde metallique enrobees a faible taux de dissolution, procedes de preparation et utilisation dans les systemes electrochimiques
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
WO2007121269A2 (en) 2006-04-11 2007-10-25 Ardea Biosciences, Inc. N-aryl-n'alkyl sulfamides as mek inhibitors
ATE483463T1 (de) 2006-04-18 2010-10-15 Ardea Biosciences Inc Pyridonsulfonamide und pyridonsulfamide als mek- hemmer
CA2656364C (en) 2006-07-06 2014-11-25 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
CA2656566C (en) 2006-07-06 2014-06-17 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CA2656618C (en) 2006-07-06 2014-08-26 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
WO2008016123A1 (en) * 2006-08-03 2008-02-07 Takeda Pharmaceutical Company Limited GSK-3β INHIBITOR
CN101583616B (zh) * 2006-08-21 2012-05-30 健泰科生物技术公司 氮杂苯并噻吩基化合物及使用方法
EP2069354B1 (en) * 2006-08-21 2011-11-02 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
AU2007286807B2 (en) * 2006-08-21 2013-03-21 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
PL2101759T3 (pl) 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
WO2008125820A1 (en) * 2007-04-13 2008-10-23 Astrazeneca Ab Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
US8509487B2 (en) * 2007-04-19 2013-08-13 Avago Technologies General Ip (Singapore) Pte. Ltd. System and method for optically measuring a parameter of an object
JP5580735B2 (ja) 2007-06-12 2014-08-27 ジェネンテック， インコーポレイテッド Ｎ−置換アザインドール類及び使用方法
KR101624361B1 (ko) * 2007-07-05 2016-05-25 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AR067413A1 (es) 2007-07-05 2009-10-07 Genentech Inc Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
MX2010004074A (es) * 2007-10-15 2010-07-02 Astrazeneca Ab Combinacion 059.
WO2009064675A1 (en) 2007-11-12 2009-05-22 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
WO2009085983A1 (en) 2007-12-19 2009-07-09 Genentech, Inc. 5-anilinoimidazopyridines and methods of use
ATE513832T1 (de) 2007-12-19 2011-07-15 Genentech Inc 8-anilinoimidazopyridine und ihre verwendung als antikrebsmittel und/oder entzündungshemmende mittel
EP2234982A1 (en) 2007-12-20 2010-10-06 F. Hoffmann-La Roche AG Substituted hydantoins as mek kinase inhibitors
BRPI0819505A2 (pt) 2007-12-21 2017-04-04 Genentech Inc "composto, composição farmacêutica, método para inibir o crescimento celular anormal e método para tratar uma doença inflamatória"
KR101624752B1 (ko) 2008-01-09 2016-05-26 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 저해물질로써의 수산화된 피리미딜 시클로펜탄
EP2247578B1 (en) * 2008-01-09 2013-05-22 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
WO2009157167A1 (ja) 2008-06-23 2009-12-30 パナソニック株式会社 無線通信基地局装置および参照信号割当方法
AU2009266956B2 (en) 2008-07-01 2014-03-20 Genentech, Inc. Bicyclic heterocycles as MEK kinase inhibitors
KR20110028376A (ko) 2008-07-01 2011-03-17 제넨테크, 인크. Ｍｅｋ 키나제 억제제로서의 이소인돌론 유도체 및 사용 방법
EA018539B1 (ru) 2008-08-04 2013-08-30 Мерк Патент Гмбх Фениламино-изоникотинамидные соединения
CN101653607B (zh) * 2008-08-19 2013-02-13 鼎泓国际投资（香港）有限公司 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
EP2358202B1 (en) * 2008-11-03 2016-06-15 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
CA2742945A1 (en) 2008-11-10 2010-05-14 Bayer Schering Pharma Aktiengesellschaft Substituted sulphonamido phenoxybenzamides
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
WO2011047795A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
CA2777071A1 (en) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
WO2011047788A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
KR20130048293A (ko) 2010-06-25 2013-05-09 노파르티스 아게 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
CN103221043B (zh) 2010-08-05 2016-04-06 卡斯西部储备大学 用于治疗神经元连接发育障碍的erk抑制剂
EP3170813B1 (en) 2010-10-06 2018-12-12 GlaxoSmithKline LLC Benzimidazole derivatives as pi3 kinase inhibitors
CA2816188A1 (en) 2010-10-29 2012-05-03 Marion Hitchcock Substituted phenoxypyridines
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
KR101975688B1 (ko) 2010-12-22 2019-05-07 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
PT2655375E (pt) 2010-12-23 2015-03-02 Sanofi Sa Derivados de pirimidinona, sua preparação e sua utilização farmacêutica
JP2014512354A (ja) 2011-04-01 2014-05-22 ジェネンテック， インコーポレイテッド Ａｋｔ阻害剤化合物及びエルロチニブの組み合わせ、及び使用方法
ES2688809T3 (es) 2011-04-01 2018-11-07 Genentech, Inc. Combinaciones de compuestos inhibidores de AKT y MEK para tratar el cáncer
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
US20140228418A1 (en) * 2011-05-23 2014-08-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
US9833439B2 (en) 2011-05-25 2017-12-05 Universite Paris Descartes ERK inhibitors for use in treating spinal muscular atrophy
EP3409278B8 (en) 2011-07-21 2020-11-04 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
AU2012333092B2 (en) * 2011-08-31 2016-04-21 Novartis Ag Synergistic combinations of PI3K- and MEK-inhibitors
US9034909B2 (en) * 2011-09-01 2015-05-19 Novartis Ag Use of organic compound for the treatment of Noonan Syndrome
EP2570127A1 (en) 2011-09-16 2013-03-20 Sanofi Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
KR102061917B1 (ko) 2011-10-14 2020-01-02 어레이 바이오파마 인크. 선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물
US20140286902A1 (en) 2011-11-02 2014-09-25 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
BR112014012539B1 (pt) 2011-11-23 2022-12-20 Medimmune, Llc Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
CN104302768A (zh) 2012-01-09 2015-01-21 诺华股份有限公司 治疗β-联蛋白相关疾病的有机组合物
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
CN103204822B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
ES2641864T3 (es) 2012-03-20 2017-11-14 Novartis Ag Terapia de combinación de un inhibidor de MEK y un inhibidor de IGF1R
EP2836873B1 (en) 2012-04-09 2020-03-11 Switch Materials, Inc. Switching materials, and compositions and methods for making same
CN104508520B (zh) 2012-05-29 2018-03-27 思维奇材料公司 包含可变透射率层的滤光片
MX2014014097A (es) 2012-05-31 2015-04-13 Bayer Pharma AG Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc).
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
CA2879252C (en) 2012-08-17 2017-10-10 F. Hoffmann-La Roche Ag Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
DK2903968T3 (en) 2012-10-02 2017-01-30 Gilead Sciences Inc INHIBITORS OF HISTON DEMETHYLASES
WO2014059422A1 (en) 2012-10-12 2014-04-17 Exelixis, Inc. Novel process for making compounds for use in the treatment of cancer
JP6243918B2 (ja) 2012-10-16 2017-12-06 トレロ ファーマシューティカルズ， インコーポレイテッド Ｐｋｍ２調節因子およびそれらの使用方法
LT3702351T (lt) 2012-10-19 2024-01-10 Array Biopharma, Inc. Kompozicijos, apimančios mek inhibitorių
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
JP6437444B2 (ja) * 2012-11-29 2018-12-12 ノバルティス アーゲー 医薬的組合せ
WO2014097125A1 (en) 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
EP2752191A1 (en) 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor
AU2014218807A1 (en) 2013-02-22 2015-09-03 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
EP3170811A1 (en) 2013-02-27 2017-05-24 Gilead Sciences, Inc. Ethyl pyridine-4-carboxylate compound as inhibitor of histone demethylases
US10139415B2 (en) 2013-02-27 2018-11-27 Daiichi Sankyo Company, Limited Method for predicting responsiveness to compound inhibiting MAPK signal transduction pathway
HUE044558T2 (hu) 2013-03-14 2019-11-28 Tolero Pharmaceuticals Inc JAK és ALK2 inhibitorok és eljárások alkalmazásukra
CN105209073A (zh) * 2013-03-21 2015-12-30 诺华股份有限公司 包含B-Raf抑制剂和第二抑制剂的组合疗法
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
MA39189A1 (fr) 2013-12-19 2017-06-30 Actelion Pharmaceuticals Ltd Dérivés de 1h-indazole et de 1h-indole antibactériens
CA2935804A1 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
CN104788365B (zh) * 2014-01-16 2018-08-10 上海艾力斯医药科技有限公司 异烟酰胺衍生物、其制备方法及应用
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR102670874B1 (ko) 2014-03-04 2024-05-31 페이트 세러퓨틱스, 인코포레이티드 개선된 재프로그래밍 방법 및 세포 배양 플랫폼
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
UY36032A (es) 2014-03-14 2015-10-30 Novartis Ag Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
AR099890A1 (es) 2014-03-31 2016-08-24 Epitherapeutics Aps Inhibidores de histona demetilasas
WO2015164228A1 (en) 2014-04-21 2015-10-29 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
CA2948077A1 (en) 2014-05-16 2015-11-19 Actelion Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives
US10023879B2 (en) 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
AU2015289672A1 (en) 2014-07-15 2017-03-02 Genentech, Inc. Compositions for treating cancer using PD-1 axis binding antagonists and MEK inhibitors
CN107074807A (zh) 2014-08-27 2017-08-18 吉利德科学公司 用于抑制组蛋白脱甲基酶的组合物和方法
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
UA120945C2 (uk) 2014-12-23 2020-03-10 Новартіс Аг Сполуки триазолопіримідину та їх застосування
JP6800859B2 (ja) 2015-01-26 2020-12-16 フェイト セラピューティクス，インコーポレイテッド 造血細胞分化を誘導するための方法および組成物
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
CR20170410A (es) 2015-03-10 2017-11-08 Aduro Biotech Inc Composiciones y métodos para activar la señalización dependiente del "estimulador del gen interferon"
EP3274344B1 (en) 2015-03-25 2019-04-24 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors
MA41866A (fr) 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
HUE055469T2 (hu) 2015-07-29 2021-11-29 Novartis Ag A LAG-3 elleni antitest molekulákat tartalmazó kombinált terápiák
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
AR105646A1 (es) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
US20190060309A1 (en) 2015-08-28 2019-02-28 Novartis Ag Mdm2 inhibitors and combinations thereof
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
EP3362570A4 (en) 2015-10-16 2019-03-20 Fate Therapeutics, Inc. PLATFORM FOR THE INDUCTION AND MAINTENANCE OF BASIC STATUS PLURIPOTENCE
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
EP3371314B1 (en) 2015-11-04 2023-07-05 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
KR20250033315A (ko) 2015-11-04 2025-03-07 페이트 세러퓨틱스, 인코포레이티드 조혈 세포 분화를 유도하기 위한 방법 및 조성물
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
WO2017127755A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
CN116376826A (zh) 2016-01-20 2023-07-04 菲特治疗公司 用来在过继性免疫疗法中进行免疫细胞调节的组合物和方法
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
FI3463345T3 (fi) 2016-06-03 2023-01-31 Farmaseuttisia yhdistelmiä
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
CN109906224B (zh) 2016-06-20 2022-02-25 诺华股份有限公司 三唑吡啶化合物及其应用
EP3472168B1 (en) 2016-06-20 2024-01-10 Novartis AG Crystalline forms of triazolopyrimidine compound
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018065924A1 (en) * 2016-10-04 2018-04-12 Sun Pharmaceutical Industries Limited Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
CN108084078B (zh) * 2016-11-24 2021-07-30 中山大学 一种治疗银屑病性关节炎疾病的药物阿普斯特的合成方法
WO2018106595A1 (en) 2016-12-05 2018-06-14 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3372624A1 (en) 2017-03-06 2018-09-12 Henkel AG & Co. KGaA One component composition based on compounds with at least two exo-vinylene cyclic carbonate units
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3712133B1 (en) * 2017-11-14 2025-12-24 Shenzhen TargetRx, Inc. Substituted benzimidazole compound and composition comprising same
US20200277378A1 (en) 2017-11-16 2020-09-03 Novartis Ag Combination therapies
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
TWI790364B (zh) 2018-03-19 2023-01-21 日商大鵬藥品工業股份有限公司 包含烷基硫酸鈉之醫藥組合物
WO2019195753A1 (en) 2018-04-05 2019-10-10 Tolero Pharmaceuticals, Inc. Axl kinase inhibitors and use of the same
EP3802609A2 (en) 2018-05-24 2021-04-14 Janssen Biotech, Inc. Psma binding agents and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR102865113B1 (ko) 2018-07-25 2025-09-26 어드밴스드 엑셀러레이터 어플리케이션즈 안정한 농축 방사성 핵종 복합체 용액
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
MX2021000977A (es) 2018-07-26 2021-04-12 Sumitomo Pharma Oncology Inc Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
DK3837256T3 (da) 2018-08-17 2023-05-30 Novartis Ag Ureaforbindelser og sammensætninger som smarca2/brm-atpase-hæmmere
JP7358484B2 (ja) 2018-09-25 2023-10-10 アドヴァンスド・アクセラレーター・アプリケーションズ・（イタリー）・エッセエッレエッレ 併用療法
JP7546297B2 (ja) 2018-11-20 2024-09-06 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのチエニル－アニリン化合物
CN113473986B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤疾病萘啶酮苯胺化合物
MA55141A (fr) 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés cyanoaryl-aniline pour le traitement d'affections de la peau
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
JP7662528B2 (ja) 2019-02-12 2025-04-15 スミトモ ファーマ アメリカ， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
JP7547360B2 (ja) 2019-03-22 2024-09-09 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法
WO2020212832A1 (en) * 2019-04-16 2020-10-22 Alembic Pharmaceuticals Limited Process of preparation of benzimidazole compounds
MA55717A (fr) 2019-04-19 2022-02-23 Janssen Biotech Inc Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
JP7763753B2 (ja) 2019-09-26 2025-11-04 ノバルティス アーゲー アザキノリン化合物およびその使用
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021116901A1 (en) * 2019-12-09 2021-06-17 Biocon Limited Forms of binimetinib and process for preparation thereof
JP2023507190A (ja) 2019-12-20 2023-02-21 ノバルティス アーゲー 増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4122925A4 (en) * 2020-03-17 2024-04-17 Medshine Discovery Inc. PROTEOLYSIS REGULATOR AND METHOD OF USE
TW202200146A (zh) 2020-04-10 2022-01-01 日商大鵬藥品工業股份有限公司 使用有3,5-二取代苯炔基化合物與mek抑制劑之癌症治療法
JP7312335B2 (ja) 2020-06-09 2023-07-20 アレイ バイオファーマ インコーポレイテッド Ｂｒａｆ関連疾患および障害を処置するための４－オキソ－３，４－ジヒドロキナゾリノン化合物
US20230321067A1 (en) 2020-06-23 2023-10-12 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
AR123185A1 (es) 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022074011A1 (en) 2020-10-05 2022-04-14 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
CN112679438A (zh) * 2020-12-31 2021-04-20 武汉九州钰民医药科技有限公司 制备司美替尼的方法
CN112759552A (zh) * 2020-12-31 2021-05-07 武汉九州钰民医药科技有限公司 司美替尼的合成方法
US12141240B2 (en) 2021-01-20 2024-11-12 Rutgers, The State University Of New Jersey Method of calibration using master calibration function
JP2024503893A (ja) * 2021-01-21 2024-01-29 エヌフレクション セラピューティクス インコーポレイテッド ピロロピリジン－アニリン化合物を調製するための方法
JP2024504758A (ja) 2021-01-28 2024-02-01 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ結合タンパク質及びその使用
WO2022169780A1 (en) 2021-02-02 2022-08-11 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
US20240207257A1 (en) * 2021-04-15 2024-06-27 Ideaya Biosciences, Inc. Combination therapy comprising a pkc inhibitor and a mek inhibitor
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2022251193A1 (en) 2021-05-27 2022-12-01 Mirati Therapeutics, Inc. Combination therapies
IL307964A (en) 2021-06-09 2023-12-01 Chugai Pharmaceutical Co Ltd Combined treatment for cancer
WO2022262699A1 (zh) * 2021-06-17 2022-12-22 深圳市塔吉瑞生物医药有限公司 取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
MX2024000313A (es) 2021-07-09 2024-03-06 Plexium Inc Compuestos de arilo y composiciones farmaceuticas que modulan la ikzf2.
MX2024005107A (es) 2021-11-04 2024-05-14 Hoffmann La Roche Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
WO2023084489A1 (en) 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating coronavirus disease 2019
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
AR129382A1 (es) 2022-05-20 2024-08-21 Novartis Ag Conjugados de anticuerpo-fármaco inhibidores de bcl-xl y met y sus métodos de uso
CN119604315A (zh) 2022-05-20 2025-03-11 诺华股份有限公司 Epha2 bcl-xl抑制剂抗体-药物缀合物及其使用方法
WO2023238000A1 (en) * 2022-06-06 2023-12-14 Glenmark Life Sciences Limited Process for preparation of selumetinib and salts thereof
EP4618994A1 (en) 2022-11-18 2025-09-24 F. Hoffmann-La Roche AG Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
EP4656193A1 (en) 2023-04-06 2025-12-03 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumors
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
FR3159741A1 (fr) 2024-03-04 2025-09-05 Pierre Fabre Medicament Formulation topique comprenant du binimetinib
WO2025215536A1 (en) 2024-04-10 2025-10-16 Novartis Ag Macrocyclic panras inhibitors for the treatment of cancer
PL451050A1 (pl) * 2025-01-27 2025-08-04 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL451047A1 (pl) * 2025-01-27 2025-08-18 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL451048A1 (pl) * 2025-01-27 2025-08-04 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL451049A1 (pl) * 2025-01-27 2025-08-04 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL248506B1 (pl) * 2025-01-27 2025-12-22 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL451046A1 (pl) * 2025-01-27 2025-06-09 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980001113A1 (fr) 1978-11-20 1980-05-29 Braun Ag Garde-temps, en particulier horloge pilotee a quartz
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5250554A (en) * 1989-10-24 1993-10-05 Takeda Chemical Industries, Ltd. Benzimidazole derivatives useful as angiotensin II inhibitors
US5218356A (en) * 1991-05-31 1993-06-08 Guenther Knapp Wireless indoor data relay system
US5216003A (en) * 1992-01-02 1993-06-01 G. D. Searle & Co. Diacid-containing benzimidazole compounds for treatment of neurotoxic injury
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
EP0710654A4 (en) 1993-07-23 1996-08-28 Green Cross Corp TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
CZ104795A3 (en) 1994-04-29 1996-02-14 Lilly Co Eli Benzimidazole derivative, process of its preparation, its use for preparing a pharmaceutical preparation and the pharmaceutical composition containing thereof
US5520187A (en) * 1994-11-25 1996-05-28 General Electric Company Ultrasonic probe with programmable multiplexer for imaging systems with different channel counts
US5525625A (en) 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ATE198326T1 (de) 1995-04-20 2001-01-15 Pfizer Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf
US5972980A (en) * 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
ES2183905T3 (es) 1995-12-20 2003-04-01 Hoffmann La Roche Inhibidores de metaloproteasa de matriz.
GB9600344D0 (en) * 1996-01-09 1996-03-13 Lilly Co Eli Benzimidzolyl neuropeptide y receptor antagonists
IL127567A0 (en) 1996-07-18 1999-10-28 Pfizer Phosphinate based inhibitors of matrix metalloproteases
EA199900139A1 (ru) 1996-08-23 1999-08-26 Пфайзер, Инк. Производные арилсульфониламиногидроксамовой кислоты
AU5131998A (en) 1997-01-06 1998-08-03 Pfizer Inc. Cyclic sulfone derivatives
WO1998033768A1 (en) 1997-02-03 1998-08-06 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
CA2279863A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
JP3710489B2 (ja) 1997-02-11 2005-10-26 ファイザー・インク アリールスルホニルヒドロキサム酸誘導体
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6821963B2 (en) * 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
IL132840A (en) 1997-07-01 2004-12-15 Warner Lambert Co Derivatives 4 - bromo or 4 - benzohydroxamic acid iodine amino iodine and pharmaceutical preparations containing them for use as MEK inhibitors
US6506798B1 (en) * 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
ES2274572T3 (es) 1997-07-01 2007-05-16 Warner-Lambert Company Llc Derivados de acido 2-(4-bromo- o 4-yodo-fenilamino) benzoico y su uso como inhibidor de mek.
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
US6534503B1 (en) * 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
IL144103A0 (en) 1999-01-07 2002-05-23 Warner Lambert Co Antiviral method using mek inhibitors
BR9916785A (pt) 1999-01-07 2001-10-23 Warner Lambert Co Tratamento de asma com inibidores mek
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
US6440966B1 (en) 1999-01-13 2002-08-27 Warner-Lambert Company Benzenesulfonamide derivatives and their use as MEK inhibitors
JP2002534446A (ja) 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー ４′ヘテロアリールジアリールアミン
CA2349467A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
DE69926800T2 (de) * 1999-01-13 2006-05-18 Warner-Lambert Company Llc Benzoheterozyklen und ihre verwendung als mek inhibitoren
JP2000204077A (ja) 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
EP1144394B1 (en) 1999-01-13 2005-08-24 Warner-Lambert Company LLC 1-heterocycle substituted diarylamines
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
WO2001005390A2 (en) * 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
EP1202732A2 (en) 1999-07-16 2002-05-08 Warner-Lambert Company Llc Method for treating chronic pain using mek inhibitors
US7030119B1 (en) * 1999-07-16 2006-04-18 Warner-Lambert Company Method for treating chronic pain using MEK inhibitors
AU5912500A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
HUP0202623A3 (en) 1999-07-16 2003-03-28 Warner Lambert Co Method for treating chronic pain using mek inhibitors
WO2001021634A1 (en) 1999-09-21 2001-03-29 Lion Bioscience Ag Benzimidazole derivatives and combinatorial libraries thereof
EP1339702A1 (en) 2000-03-15 2003-09-03 Warner-Lambert Company 5-amide substituted diarylamines as mek inhibitors
MXPA02008103A (es) 2000-03-15 2002-11-29 Warner Lambert Co Diarilaminas sustituidas con 5-amida como inhibidores mek.
JP3811775B2 (ja) * 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
SK2072003A3 (en) 2000-08-25 2004-01-08 Warner Lambert Co Process for making N-aryl-anthranilic acids and their derivatives
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
US20070004713A1 (en) * 2000-12-07 2007-01-04 Bernard Barlaam Therapeutic benimidazole compounds
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
WO2002072548A2 (en) * 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
US20040039208A1 (en) 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
AU2002341715A1 (en) * 2001-09-17 2003-04-01 Bristol-Myers Squibb Company Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
AU2002348791A1 (en) 2001-12-21 2003-07-09 Warner-Lambert Company Llc Modified mek1 and mek2, crystal of a peptide: ligand: cofactor complex containing such modified mek1 or mek2, and methods of use thereof
JP2005515253A (ja) 2002-01-23 2005-05-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｎ−（４−置換フェニル）−アントラニル酸ヒドロキサメートエステル
IL163996A0 (en) * 2002-03-13 2005-12-18 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
UA77765C2 (en) 2002-03-13 2007-01-15 Array Biopharma Inc N3 alkylated derivatives of benzimidazole as mek inhibitors
DE10238002A1 (de) * 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
US7504426B2 (en) * 2002-09-06 2009-03-17 Janssen Pharmaceutica N.V. Heterocyclic compounds
US20040127395A1 (en) * 2002-09-06 2004-07-01 Desai Pragnya J. Use of histamine H4 receptor modulators for the treatment of allergy and asthma
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
ATE442847T1 (de) 2003-07-24 2009-10-15 Warner Lambert Co Benzimidazol-derivate als mek-hemmer
DE102005032379A1 (de) 2005-07-08 2007-01-11 Conti Temic Microelectronic Gmbh Zugangskontrollsystem für ein Kraftfahrzeug
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
WO2014097125A1 (en) 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib

Also Published As

Publication number Publication date
LUC00100I2 (cg-RX-API-DMAC7.html) 2020-01-23
AU2003218157A1 (en) 2003-09-29
PT2130537E (pt) 2012-12-20
TW201031642A (en) 2010-09-01
RU2004127926A (ru) 2005-06-27
SG2013013339A (en) 2014-12-30
CN1652776A (zh) 2005-08-10
US8003805B2 (en) 2011-08-23
UA77765C2 (en) 2007-01-15
EP2130536A1 (en) 2009-12-09
NL300974I2 (nl) 2022-04-06
CL2012002381A1 (es) 2012-11-05
US7777050B2 (en) 2010-08-17
CY1109727T1 (el) 2014-09-10
DK2130537T3 (da) 2013-02-18
ES2335276T3 (es) 2010-03-24
IS2999B (is) 2018-06-15
CY1119136T1 (el) 2018-02-14
ES2407849T3 (es) 2013-06-14
DOP2013000023A (es) 2013-06-30
PL401637A1 (pl) 2013-05-27
PL230179B1 (pl) 2018-09-28
WO2003077914A1 (en) 2003-09-25
KR20040094786A (ko) 2004-11-10
US20030232869A1 (en) 2003-12-18
TWI343377B (en) 2011-06-11
ATE449605T1 (de) 2009-12-15
US20050143438A1 (en) 2005-06-30
SI2275102T1 (sl) 2015-12-31
HUE025767T2 (en) 2016-05-30
PL401635A1 (pl) 2013-05-27
SI2130537T1 (sl) 2013-01-31
EP2130537B1 (en) 2012-11-14
JP5498546B2 (ja) 2014-05-21
US20100260714A1 (en) 2010-10-14
IS8960A (is) 2011-06-16
RU2307831C9 (ru) 2008-06-10
DK3000810T3 (en) 2017-10-16
AR090144A2 (es) 2014-10-22
HK1141976A1 (en) 2010-11-26
PT3000810T (pt) 2017-10-25
PL401638A1 (pl) 2013-05-27
US20100261718A1 (en) 2010-10-14
ZA200407220B (en) 2007-05-30
FR19C1014I1 (fr) 2019-04-19
US20080171778A1 (en) 2008-07-17
AU2009222613B2 (en) 2011-06-16
KR100984595B1 (ko) 2010-09-30
DOP2003000613A (es) 2003-09-30
IS2998B (is) 2018-06-15
CA2478374A1 (en) 2003-09-25
IL163995A0 (en) 2005-12-18
CY2019012I1 (el) 2020-05-29
JP2008163034A (ja) 2008-07-17
DOP2011000109A (es) 2011-11-30
PL233177B1 (pl) 2019-09-30
TW201031641A (en) 2010-09-01
IL204420A (en) 2012-12-31
PT2275102E (pt) 2015-10-27
RU2307831C2 (ru) 2007-10-10
US7973170B2 (en) 2011-07-05
EP3000810B1 (en) 2017-07-19
US8513293B2 (en) 2013-08-20
AR038971A1 (es) 2005-02-02
IS7442A (is) 2004-09-09
PL377628A1 (pl) 2006-02-06
LTPA2019007I1 (lt) 2019-03-25
KR100984573B1 (ko) 2010-09-30
US20120277277A1 (en) 2012-11-01
EP2275102B1 (en) 2015-07-29
FR19C1014I2 (fr) 2020-03-13
JP2012224649A (ja) 2012-11-15
IS8959A (is) 2011-06-16
JP2008019277A (ja) 2008-01-31
JP2005530709A (ja) 2005-10-13
LUC00100I1 (cg-RX-API-DMAC7.html) 2019-02-13
PL233493B1 (pl) 2019-10-31
TW200407129A (en) 2004-05-16
HK1070823A1 (en) 2005-06-30
US20100267710A1 (en) 2010-10-21
US8193229B2 (en) 2012-06-05
SG148857A1 (en) 2009-01-29
US8193231B2 (en) 2012-06-05
CN101633645B (zh) 2011-06-22
TWI338685B (en) 2011-03-11
CN101633644B (zh) 2012-05-09
US7576114B2 (en) 2009-08-18
US20080177082A1 (en) 2008-07-24
IL204419A (en) 2012-12-31
BR122018007328B1 (pt) 2020-03-03
IL204420A0 (en) 2011-07-31
IS2990B (is) 2017-12-15
AU2003218157B2 (en) 2009-07-09
EP2275102A1 (en) 2011-01-19
SG194238A1 (en) 2013-11-29
MXPA04008893A (es) 2005-06-20
KR20100040760A (ko) 2010-04-20
KR100984613B1 (ko) 2010-09-30
NZ535158A (en) 2007-06-29
US7425637B2 (en) 2008-09-16
US20110158971A1 (en) 2011-06-30
EP2130536B1 (en) 2013-05-08
CN100519539C (zh) 2009-07-29
CY2019012I2 (el) 2020-05-29
SI1482932T1 (sl) 2010-02-26
CN101486682B (zh) 2013-08-14
IS2748B (is) 2011-08-15
US8178693B2 (en) 2012-05-15
ES2549159T3 (es) 2015-10-23
DE60330227D1 (de) 2010-01-07
JP4093966B2 (ja) 2008-06-04
AR090143A2 (es) 2014-10-22
CL2012002380A1 (es) 2012-11-05
EP3000810A1 (en) 2016-03-30
ES2394347T3 (es) 2013-01-30
PL401636A1 (pl) 2013-05-27
US20100261717A1 (en) 2010-10-14
TWI350285B (en) 2011-10-11
DK1482932T3 (da) 2010-02-01
AU2009222613A1 (en) 2009-10-29
CN101633645A (zh) 2010-01-27
EP1482932A1 (en) 2004-12-08
PT1482932E (pt) 2010-01-12
AU2003218157C1 (en) 2011-11-24
BE2019C510I2 (cg-RX-API-DMAC7.html) 2022-05-19
US8193230B2 (en) 2012-06-05
CN101633644A (zh) 2010-01-27
KR20100040759A (ko) 2010-04-20
JP5102642B2 (ja) 2012-12-19
BR122018007328B8 (pt) 2021-05-25
DOP2011000110A (es) 2011-11-30
DK2275102T3 (en) 2015-11-02
IL204419A0 (en) 2011-07-31
EP2130537A1 (en) 2009-12-09
CA2478374C (en) 2009-01-06
HUS1900011I1 (hu) 2019-04-29
EP1482932B1 (en) 2009-11-25
IL163995A (en) 2010-11-30
IS8961A (is) 2011-06-16
LTC1482932I2 (lt) 2020-04-27
PA8569301A1 (es) 2004-10-08
HK1153139A1 (en) 2012-03-23
US20100267793A1 (en) 2010-10-21
CN101486682A (zh) 2009-07-22
ES2635666T3 (es) 2017-10-04
EP1482932A4 (en) 2006-04-05

Similar Documents

Publication Publication Date Title
PT3000810T (pt) Derivados de benzimidazole alquilado n3 como inibidores de mek
IL163996A0 (en) N3 alkylated benzimidazole derivatives as mek inhibitors
IL173935A0 (en) N3 alkylated benzimidazole derivatives as mek inhibitors
IL165810A0 (en) Novel benzimidazole derivatives
SI1492785T1 (sl) 2-hidroksi-3-heteroarilindolni derivati kot inhibitorji GSK3
ATE386518T1 (de) Benzimidazolderivate
AU2003222206A1 (en) Novel benzimidazole compounds
HRP20050162A2 (en) ?-lactamase inhibitor prodrug
AU2003303051A8 (en) Cell death inhibitor
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
HK1070586A (en) N3 alkylated benzimidazole derivatives as mek inhibitors
HK1070065A (en) Novel benzimidazole derivatives
SE0203621L (sv) Kosttillskott